Prozkoumejte nejčtenější články a videa na Campus Sanofi
Agalsidase-β should be proposed as first line therapy in classic male Fabry patients with undetectable α-galactosidase A activity Nowak A, et al. Mol Genet Metab. 2022 Sep-Oct;137(1-2):173-178.